Please login to the form below

Not currently logged in
Email:
Password:

oxycodone

This page shows the latest oxycodone news and features for those working in and with pharma, biotech and healthcare.

FDA committee rejects Intellipharmaceutics’ opioid drug Aximris

FDA committee rejects Intellipharmaceutics’ opioid drug Aximris

Verdict closely follows rejection of Nektar’s opioid analgesic. The FDA’s Anesthetic and Analgesic Committee has rejected yet another opioid drug – this time Intellipharmaceutics’ extended-release oxycodone tablet Aximiris. . ... Aximris was

Latest news

More from news
Approximately 2 fully matching, plus 21 partially matching documents found.

Latest Intelligence

  • The transatlantic opioid crisis The transatlantic opioid crisis

    A landmark ruling by a judge in Oklahoma, USA awarded the state record damages of $572m (£468m) from Johnson &Johnson (J&J), the manufacturer of synthetic opioids like oxycodone and fentanyl

  • Pharma deals during November 2013 Pharma deals during November 2013

    The licence is for tamper resistant oxycodone (marketed in the US since 2010) and an oxycodone/naloxone combination marketed in Europe since 2009.

  • Pharma deals during October 2012 Pharma deals during October 2012

    34. ††QRxPharma / Paladin Labs. Licence. MoxDuo IR, fixed dose morphine and oxycodone for pain (NDA filed).

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Wisepress

Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...

Latest intelligence

Are you ready for the digital health revolution?
In this edition of Delta magazine, we explore how rapid digitalization has transformed the care pathway and reveal how life science companies can succeed in the digital age....
#DemandDiversity: Can new medical publication guidelines help fix diversity in clinical trials?
Over the last 8 months, JAMA have been working on a new set of guidelines for research papers looking to publish with them, which is summarised in their latest editorial...
DATA shutterstock_1818502577-640.jpg
Empowering patients empowers results
Patient-centricity is key when it comes to creating a more flexible, efficient and modern process for clinical trials...

Infographics